Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
Go back to Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator| LIGAND PHARMA (NASDAQ: LGND) | Delayed: 262.17 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $262.17 | 52 Week High | $139.79 | |||
| Open | $262.17 | 52 Week Low | $82.07 | |||
| Day High | $262.17 | P/E | 609.70 | |||
| Day Low | $262.17 | EPS | $0.43 | |||
| Volume | 235,858 | |||||
| XOMA (NASDAQ: XOMA) | Delayed: 42.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $42.00 | 52 Week High | $7.33 | |||
| Open | $42.00 | 52 Week Low | $0.34 | |||
| Day High | $42.00 | P/E | N/A | |||
| Day Low | $42.00 | EPS | $-0.73 | |||
| Volume | 250 | |||||
